Search
ceftolozane tazobactam (Zerbaxa)
Indications:
- complicated urinary tract infections, including pyelonephritis
- complicated intra-abdominal infections combined with metronidazole
- multidrug-resistant Pseudomonas aeruginosa combined with colistin [2]
- hospital-acquired pneumonia; ventilator-associated pneumonia [3] (FDA-approved)
Contraindications:
- reduced efficacy in patients with eGFR < 50 mL/min/1.75 m2
Dosage:
- IV dosing every 8 hours
Antimicrobial activity:
- Pseudomonas aeruginosa
Adverse effects:
- similar to other cephalosporins
- elevated liver enzyme levels, renal dysfunction, & diarrhea
Mechanism of action:
- anti-pseudomonal cephalosorin with beta-lactamase inhibitor
- inhibits cell wall synthesis by binding penicillin-binding protein
- combined with beta-lactamase
General
antibiotic combination
References
- Zuger A
The Newest Antibiotics on the Block.
NEJM Journal Watch. June 13, 2016
Massachusetts Medical Society
(subscription needed) http://www.jwatch.org
- Deak D et al.
Progress in the fight against multidrug-resistant bacteria?
A review of U.S. Food and Drug Administration-approved
antibiotics, 2010-2015.
Ann Intern Med 2016 May 31
PMID: 27239977
- Medical Knowledge Self Assessment Program (MKSAP) 18,
American College of Physicians, Philadelphia 2018
- FDA News Release. June 3, 2019
FDA approves new treatment for hospital-acquired and ventilator-
associated bacterial pneumonia.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia
Components
ceftolozane
tazobactam